A Phase Ib Open-label, Multicenter Cross-over Study to Investigate the Effect of Food on the Rate and Extent of Oral LBH589 Absorption in Patients With Advanced Solid Tumors

Inclusion Criteria

Inclusion criteria:

- Patients with advanced solid tumors whose disease has progressed despite standard
therapy or for whom no standard therapy exists

- Age ≥ 18 years old

- Patients must have adequate laboratory values

- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

- Ability to swallow capsules or tablets

Exclusion criteria:

- Patients with active central nervous system (CNS) disease or brain metastases except
those who have been previously treated and have been stable for at least 3 months.

- Patients with a second primary malignancy that is currently clinically significant or
requiring active intervention

- Impaired heart function or clinically significant heart disease

- Impairment of gastrointestinal (GI) function, or GI disease that may significantly
alter the absorption of LBH589

- Ongoing diarrhea

- Liver or renal disease with impaired hepatic or renal functions

- Concomitant use of any anti-cancer therapy or certain drugs

- Female patients who are pregnant or breast feeding

- Patients not willing to use an effective method of birth control

Other protocol-defined inclusion/exclusion criteria may apply